Membrane in Medical Technology

Cystic Fibrosis - Liposomal Tobramycin Receives Second Orphan Drug Designation Within Weeks

... of infection, tobramycin-containing liposomes seem to fuse with the cell membrane of the pathogen. In this way, the entire load of tobramycin contained in ... is triggered when the liposomes undergo a fusion process with the outer membrane of the bacterial cell wall. Tobramycin then penetrates into the inner cell ...

Osteotech Completes Enrollment for DuraTech(TM) BioRegeneration Matrix Clinical Trial

... platform, DuraTech is used to repair dura mater (the tough, outermost membrane surrounding the brain and spinal cord) during cranial surgical procedures. ... and is designed to be utilized to repair the dura mater, a fibrous membrane that protects the brain and the spinal cord, when the dura mater has been ...

Myelin Removal Beads: Premium Efficiency for Neural Cell Separations and Antibody Stainings

... and exclusive release of Myelin Removal Beads. Myelin is a specialized membrane which ensheathes and insulates axons in the peripheral and central nervous system. During preparation of single-cell suspensions, myelin membrane fragments represent the major contaminant. "When dissociating adult neural ...

D-Pharm Submits Investigational New Drug Application and Special Protocol Assessment to the FDA for Phase III Trial of DP-b99 in Acute Stroke Patients

... a randomized, double blind, placebo-controlled study (study acronym MACSI: membrane Activated Chelator Stroke Intervention). It is designed to compare the ... occurring in stroke patients and emerged from D-Pharm's proprietary membrane Activated Chelator (MAC) platform technology. D-Pharm successfully ...

Potentia Pharmaceuticals' POT-4 Drug Candidate for Age-Related Macular Degeneration Successfully Completes Phase I Clinical Trial - Prepares for Phase II

... process involving dozens of plasma proteins, ultimately leading to cell membrane disruption through the membrane attack complex (MAC). Activation of the complement system is an important ...

Study Shows Leconotide, an Investigative Calcium Channel Blocker, Has Potential as a Selective, Efficacious, Non-Opioid Pain Treatment

... Calcium Channel Blockers Every cell in the body is enclosed by a membrane which acts as a barrier controlling the flow of chemicals into and out of the cell. Channels through the membrane control the passage of substances into and out of the cell. Some are ...

Osteotech Initiates Pivotal Clinical Trial for DuraTech(TM) BioRegeneration Matrix

... surgical procedures, the patients' dura mater (the tough, outermost membrane surrounding the brain and spinal cord) was successfully repaired by ... and is designed to be utilized to repair the dura mater, a fibrous membrane that protects the brain and the spinal cord, when the dura mater has been ...

Study Shows Benefits of a High Omega-3 Diet in Older Adults

... secretion and cell responsiveness decrease, possibly due to loss of cell membrane fluidity or alteration of the membrane," said Dr. S. Mitchell Harman, MD, ... known level of omega-3 than previous studies. During the last week, membrane fatty acids were measured on each diet. Insulin sensitivity was also ...

Medarex Announces Allowance of Investigational New Drug Applications for Wholly Owned Fully Human Anti-CD19 Antibody, MDX-1342

... conditions." About CD19 and MDX-1342 CD19 is a B-cell specific membrane protein that is broadly expressed during B-cell development, from the ... monoclonal antibodies directed against CD20, another B-cell specific membrane protein that has a more restricted expression pattern than CD19 during ...

R788 in TASKi3 Clinical Trial Does Not Meet Efficacy Endpoints in RA Patients Who Had Previously Failed Biologic Therapies - Results Incongruent

... in those joints. For these scores a lower value indicates a better clinical condition. ** Synovitis: inflammation of the synovial membrane lining joints Osteitis: inflammation of the bone Safety Results Similar to TASKi2, the most common clinically meaningful ...

Cardax Pharmaceuticals Nominates Clinical Candidate Heptax for Liver Disease; Heptax Ameliorates Inflammation and Oxidative Stress Related to Liver Disease and Metabolic Syndrome

... stress while localizing in the liver and the vasculature. Cellular studies have determined that this compound acts as a plasma and mitochondrial membrane stabilizer and a potent antioxidant. "Cardax has pioneered a novel approach to treating the source of inflammation, intracellular oxidative ...

Transave Receives $2.2 Million Cystic Fibrosis Foundation Award for Development of ARIKACE(TM)

... System uses eFlow Technology to enable highly efficient aerosolization of medication including liposomal formulations via a vibrating, perforated membrane that includes thousands of laser drilled holes. Compared to other nebulization technologies, eFlow Technology produces aerosols with a very high ...

ALP Life Sciences, LLC Announces Nanoveson(TM) Patent Filing and Whitepaper Availability on Proposed Therapy for Non-Alcoholic Fatty Liver Disease (NAFLD) and Comorbid Diseases

... Nanoveson(TM) therapy utilizes only natural compounds. The therapy triggers liver triglyceride remodeling into bile phospholipids and lipid membrane fusion and aggregation in the intestines. Molecular compounds including biliary phospholipids, arachidonic acid metabolites, cholesterol, methyl ...

Data Demonstrated ACTEMRA(R) (tocilizumab) Significantly Inhibited Progression of Structural Joint Damage in Rheumatoid Arthritis Patients

... IL-6 in patients with RA. About Rheumatoid Arthritis RA is a progressive, systemic autoimmune disease characterized by inflammation of the membrane lining in the joints. This inflammation causes a loss of joint shape and function, resulting in pain, stiffness and swelling, ultimately leading to ...

PARI Pharma Reports Successful Phase Ib Clinical Results for Inhaled Liposomal Cyclosporine A and Gains FDA Orphan Drug Designation for the Prevention and Treatment of Bronchiolitis Obliterans

... eFlow Nebulizer System uses eFlow Technology to enable highly efficient aerosolization of liquid medications via a vibrating, perforated membrane that includes thousands of small holes that produce the aerosol mist. Compared to other nebulization technologies, eFlow Technology produces ...

TRACON Pharmaceuticals' Small Molecule TRC102 and Antibody TRC105 to be Presented at ASCO 2009

... with the potential for broad application to a wide variety of cancer types. TRC105 is a monoclonal antibody that binds CD105 (endoglin), a membrane receptor on endothelial cells that is required for angiogenesis. By inhibiting new blood vessel formation, the antibody is expected to have activity ...

Two-Year Data Reinforce Effect of ACTEMRA(R) (tocilizumab) in Inhibiting Progression of Joint Damage and Improving Physical Function in Rheumatoid Arthritis Patients

... IL-6 in patients with RA. About Rheumatoid Arthritis RA is a progressive, systemic autoimmune disease characterized by inflammation of the membrane lining in the joints. This inflammation causes a loss of joint shape and function, resulting in pain, stiffness and swelling, ultimately leading to ...

PARI Pharma's Nebulized DSCG Shows Results Similar to Inhaled Steroids in Asthma Studies Presented at ATS

... eFlow Nebulizer System uses eFlow Technology to enable highly efficient aerosolization of liquid medications via a vibrating, perforated membrane that includes thousands of small holes that produce the aerosol mist. Compared to other nebulization technologies, eFlow Technology produces ...

Oxford BioTherapeutics and GlaxoSmithKline Form Strategic Alliance to Develop Novel Cancer Therapeutic Antibodies

... on its OGAP(R) proteomic database, which represents one of the world's largest proprietary human protein collections including data on 5,000 cancer membrane proteins combined with highly disease relevant genomic and clinical information derived from human blood and cancer tissue studies. "We are ...

Essentialis Meets Primary Endpoint in Phase 2b Trial of DCCR for Treatment of Hypertriglyceridemia and is Granted Extensive Patent Coverage in the US

... and metabolic diseases. The company's portfolio of products is targeted at the ATP-sensitive potassium channel, a metabolically-regulated membrane protein whose modulation has the potential to impact a wide range of cardiovascular and metabolic diseases. The company's lead product has completed ...

Peregrine Pharmaceuticals Completes Patient Enrollment in its Phase II Trial of Bavituximab Plus Docetaxel in Breast Cancer Patients

... breast cancer in 2008 and 40,480 women died of the disease in the U.S. alone. Bavituximab is a monoclonal antibody that binds to the cellular membrane component phosphatidylserine (PS) that is usually located inside cells, but which becomes exposed on the outside of the cells that line the blood ...

Pharmaxis Announces Positive Results of Phase 3 Cystic Fibrosis Trial

... air passages in the lungs, removing debris and bacteria. In CF, an inherited disease, a defective gene disrupts ion transport across the epithelial membrane within cells. In the lungs, this leads to a depletion of the airway surface liquid that normally bathes the cilia, and a resultant reduction in ...

Plasma Products Safe Despite Swine Influenza Outbreak, Assures International Biopharmaceutical Company Octapharma

... and Portugal. During the manufacture of Octaplas(R), the product undergoes a solvent-detergent treatment that destroys the lipid enveloped membrane of a virus, making it inactive and unable to infect. All influenza viruses are lipid enveloped viruses and not very resistant to inactivation. ...

Raptor Pharmaceuticals Receives Notices of Allowance for Two NeuroTrans(TM) Patent Applications

... crosses the BBB through transcytosis, or the selective receptor-mediated transport of peptides and large proteins across the endothelial membrane in the BBB. NeuroTrans(TM) has also been conjugated to a variety of protein drugs, including enzymes and growth factors, without interfering with ...

Data Presented at AACR Annual Meeting Show Anti-Tumor Activity of Peregrine's Fully Human Anti-PS Antibody in Prostate Cancer Model

... trials for the treatment of advanced breast cancer and non-small cell lung cancer. Peregrine's PS-targeting antibodies bind to the cellular membrane component PS that is usually located inside cells, but which becomes exposed on the external surface of the cells that line the blood vessels of ...

Studies Presented at AACR Annual Meeting Highlight Multiple Immunomodulatory Mechanisms of Peregrine's PS-Targeting Antibodies

... About Peregrine's Clinical Stage Anti-PS Antibody Bavituximab Peregrine's clinical stage PS-targeting antibody bavituximab binds to the cellular membrane component phosphatidylserine (PS) that is usually located inside cells, but which becomes exposed on the outside of the cells that line the blood ...

Peregrine Pharmaceuticals Reports Positive Preliminary Data From Phase II Bavituximab Lung Cancer Trial

... type of lung cancer, accounting for approximately 85-90% of lung cancer cases. Bavituximab is a monoclonal antibody that binds to the cellular membrane component phosphatidylserine (PS) that is usually located inside cells, but which becomes exposed on the outside of the cells that line the blood ...

Roche and FDA Agree on Pathway Towards U.S. Approval of ACTEMRA(R) (tocilizumab)

... About Rheumatoid Arthritis Rheumatoid arthritis is a progressive, systemic autoimmune disease characterized by inflammation of the membrane lining in the joints. This inflammation causes a loss of joint shape and function, resulting in pain, stiffness and swelling, ultimately leading to ...

Ipsogen Launches a New Test to Determine Tumor HER2 Status and Guide Herceptin(R) Prescription in Breast Cancer

... been developed more recently. Ipsogen's MapQuant Dx(TM) HER2 test was designed to correlate with the expression of the HER2 protein at cell membrane level. The test, developed on a set of 152 tumors, was validated in 4 independent datasets totalling 269 tumors. The test correlates with the IHC ...

Essentialis Completes Patient Enrollment in Phase 2 Trial of DDCR for Treatment of Dyslipidemia

... metabolic diseases. The company's portfolio of products is targeted at the ATP-sensitive potassium channel, a metabolically-regulated membrane protein whose modulation has the potential to impact a wide range of cardiovascular and metabolic diseases. The company's lead product is in Phase 2 ...

New Study Demonstrated ACTEMRA(R) (tocilizumab) Inhibited Progression of Joint Damage in Rheumatoid Arthritis Patients

... with RA. About Rheumatoid Arthritis Rheumatoid arthritis is a progressive, systemic autoimmune disease characterized by inflammation of the membrane lining in the joints. This inflammation causes a loss of joint shape and function, resulting in pain, stiffness and swelling, ultimately leading to ...

ACTEMRA (R) (tocilizumab) Significantly Reduced Signs and Symptoms of Rheumatoid Arthritis in Patients Who Failed Prior Treatments

... with RA. About Rheumatoid Arthritis Rheumatoid arthritis is a progressive, systemic autoimmune disease characterized by inflammation of the membrane lining in the joints. This inflammation causes a loss of joint shape and function, resulting in pain, stiffness and swelling, ultimately leading to ...

Protein Shown to Play a Key Role in Normal Development of Nervous System

... SAP97, to control dendrite growth during the early postnatal period. "Our work suggests that GluR1 brings the scaffolding protein SAP97 to the membrane of nerve cells, where it can receive pro-growth signals to build dendrites." Although both studies were performed in mice, the ...

Potentia Pharmaceuticals Announces Positive Safety Data and Study Expansion in Phase I Trial for Lead Drug Candidate POT-4

... the Complement System and POT-4 Complement activation is an inflammatory process involving dozens of plasma proteins, ultimately leading to cell membrane disruption through the membrane attack complex (MAC). Activation of the complement system is an important part of the body's defensive immune ...

Recruitment Completed in Ofatumumab NHL Pivotal Study

... Ph.D., Chief Executive Officer of Genmab. Ofatumumab is an investigational, new generation, human monoclonal antibody that targets a distinct membrane proximal, small loop epitope (specific binding site)of the CD20 molecule on the surface of B-cells. Ofatumumab is being developed to treat CLL, ...

Successful Results for Mymetics Corporation's Mucosal HIV/AIDS Vaccine Viral Challenge Significantly Exceeds Expectations

... virus entry across the mucosal tissues, the primary entry door of most pathogens. Virosomes are lipidic vesicles derived from influenza virus membrane that are non-replicative antigen carriers which possess intrinsic systemic and mucosal adjuvant properties. Virosomes are approved in 42 countries ...

Genmab Announces Upcoming Ofatumumab Studies

... primary endpoint of the study is safety. Ofatumumab is an investigational new generation human monoclonal antibody that targets a distinct, membrane proximal, small loop epitope (specific antibody binding site) of the CD20 molecule on B cells. Ofatumumab is being developed to treat chronic ...

Nemours Center for Childhood Cancer Research Team at the Alfred I. duPont Hospital for Children Identifies the Function of a Biomarker Present in Prostate Cancer Cells: New Insight into Therapeutic Benefit for Patients with Advanced Prostate Cancer

... state of cells and may be used to diagnose and treat a disease or monitor response to therapy. The discovery, titled "Prostate specific membrane antigen associates with anaphase promoting complex and induces chromosomal instability," is outlined in the July issue of Molecular Cancer ...

Bad News to Bad Bugs: Northern Antibiotics Develops Novel Polymyxins With Reduced Toxicity

... The derivatives contain three positive charges only, while polymyxin B and colistin have five. They bind to the isolated brush-border membrane of rat kidney at an affinity which is only 1/5-1/7 of that for polymyxin B. In vivo rat studies also show remarkable differences in parameters that ...

ACTEMRA(R) (tocilizumab) Significantly Reduces Rheumatoid Arthritis Signs and Symptoms Regardless of Previous Therapy in Two New Global Studies

... with RA. About Rheumatoid Arthritis Rheumatoid arthritis is a progressive, systemic autoimmune disease characterized by inflammation of the membrane lining in the joints. This inflammation causes a loss of joint shape and function, resulting in pain, stiffness and swelling, ultimately leading to ...